What is Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical enterprise dedicated to transforming the lives of patients suffering from rare neuroendocrine conditions. The company specializes in the research, development, and commercialization of precision medicines that target the underlying biological mechanisms of complex, often neglected medical disorders. By bridging the gap between advanced genetic research and clinical application, Rhythm Pharmaceuticals provides critical therapeutic options for patients who have historically faced limited treatment alternatives. Its market position is defined by a commitment to scientific rigor and a patient-centric development model that addresses significant unmet needs in the global healthcare landscape.
How much funding has Rhythm Pharmaceuticals raised?
Rhythm Pharmaceuticals has raised a total of $848.5M across 8 funding rounds:
Series A
$40M
Series B
$33M
Other Financing Round
$41M
Stock Offering
$138M
Stock Offering
$174M
Stock Offering
$172.5M
Debt
$100M
Series A
$150M
Series A (2010): $40M with participation from New Enterprise Associates (NEA), Third Rock Ventures, and MPM Capital
Series B (2012): $33M led by MPM Capital, NEA, Ipsen, Third Rock Ventures, and Pfizer Venture Investments
Other Financing Round (2017): $41M supported by Third Rock Ventures, Deerfield Management, NEA, Pfizer Venture Investments, OrbiMed, Ipsen, and MPM Capital
Stock Issuance/Offering (2017): $138M featuring Undisclosed
Stock Issuance/Offering (2018): $174M backed by Undisclosed
Stock Issuance/Offering (2019): $172.5M with participation from Undisclosed
Debt (2022): $100M led by HealthCare Royalty Partners
Series A (2024): $150M supported by Perceptive Advisors
Key Investors in Rhythm Pharmaceuticals
MPM Capital
MPM BioImpact manages early-stage venture funds, private/public impact funds and a public equities fund. We convert science into therapeutics to reach the patients that need them most.
Third Rock Ventures
Founded in 2007, Third Rock Ventures is a healthcare venture firm focused on disruptive areas of science and medicine to discover, launch and build companies that make a dramatic difference in people's lives.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains.
What's next for Rhythm Pharmaceuticals?
Looking ahead, the recent capital injection positions Rhythm Pharmaceuticals to accelerate its pipeline development and expand its commercial footprint. The company is expected to leverage this financing to deepen its research into novel therapeutic targets, potentially broadening its portfolio to address a wider array of rare diseases. As the firm transitions into its next phase of growth, strategic priorities will likely include scaling its global distribution capabilities and optimizing its clinical trial infrastructure. By maintaining its focus on precision medicine, Rhythm Pharmaceuticals is well-equipped to navigate the evolving regulatory and competitive environment, ensuring that its innovative solutions reach the patients who need them most.
See full Rhythm Pharmaceuticals company page
